CEO Update - 5 June 2023

I’m in Boston with over 200 UK companies at the annual BIO International Convention this week. It is great to see such a vibrant and positive UK presence and I’m looking forward to promoting the excellence of our ecosystem on this global stage. Read on about the core UK message at BIO this week, and details on the launch of our VPAS report.

BIA calls on government to support an attractive UK commercial environment for medicines

BIA has today published a report calling for the next Voluntary Pricing and Access Scheme (VPAS) to build on the spirit of partnership between government and life sciences industry seen during the COVID-19 pandemic.

Member spotlight: astrophysics meets life sciences at Graeme Hills

So, what do astrophysics and life sciences have in common? On the surface you may not think very much, but there is more than you would imagine.

Is it time for a new tool box for drug research and development?

In this blog, Professor James Fildes, CEO and Chief Scientist and Amy Stewart, Research Technician at Pebble Biotechnology Laboratories argue that the significant difference in human to mice gene expression in various tissues could explain why many drugs that are successful in rodents fail in humans.

Cambridge Wide Open Day to drive inclusive collaboration

o2h group launches the Cambridge Wide Open Day, offering a unique insight into the city best known as the ‘UK Centre of Science & Technology’.

Stablepharma and BB-NCIPD Ltd (Bul Bio) to develop a fridge-free Tetanus mono vaccine

Stablepharma Ltd. and BB-NCIPD Ltd. (Bul Bio) have signed a second agreement for the exclusive bulk supply and commercialization of the Tetanus vaccine (SPVX06), following a similar arrangement for the Tetanus diphtheria vaccine (SPVX02) last year.

CEO Update - 30 May 2023

Last Thursday was a big day for our sector as government and industry leaders came together for the UK Life Science Council meeting in No 10 Downing Street. It’s the pinnacle of the partnership working – forged and deepened through our joint work in the pandemic – and the BIA was at the heart of the action-progressing key agendas on behalf of members.

Member spotlight: supercharging drug discovery with Carterra

In our latest member spotlight blog, Josh Eckman, Founder and CEO of Carterra, details the Carterra's journey, from disrupting an already established industry as a start-up, to assisting in the development of the first Covid19 therapeutic antibody.

Adthera Bio breaks from stealth with venture funding and thought leadership team

Adthera bio limited, an innovative cell and gene therapy CDMO partner comes out of stealth with well-funded backing from Delin Ventures and a hugely experienced leadership team.

BIA welcomes Chancellor’s life sciences growth package

The UK Government has announced a package of investment and policy initiatives to support the continued growth of the sector following a meeting of the Chancellor, Jeremy Hunt MP, and industry leaders in Downing Street.